Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Maintenance in Advanced or Recurrent Endometrial Cancer
CTR20211721Phase 3Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selinexor in endometrial cancer (EC), sponsored by Karyopharm Therapeutics Inc.. Started Jul 2021; status: terminated.
02
Drugs
selinexor
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20211721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211721.